Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
European Journal of Nuclear Medicine and Molecular Imaging|December 1, 2016
Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesionsChristian Uprimny, Alexander Stephan Kroiss, Clemens Decristoforo, et al.
Cancers|August 1, 2020
Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate CancerMona Kafka, Fabian Mayr, Veronika Temml, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 8, 2017
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrenceChristian Uprimny, Alexander Stephan Kroiss, Josef Fritz, et al.
European Urology Focus|July 13, 2020
Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel-A Real-world Data AssessmentIgor Tsaur, Isabel Heidegger, Roderick C N van den Bergh, et al.
Wiener Klinische Wochenschrift|June 4, 2025
Use of 177Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer : Joint statement of the Austrian Society of Nuclear Medicine and Theranostics and the Austrian Society of Urology and AndrologySiroos Mirzaei, Gregor Schweighofer-Zwink, Heidemarie Ofner, et al.
Clinical Genitourinary Cancer|October 29, 2017
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate CancerDaniel Heinrich, Jasmin Bektic, Andries M Bergman, et al.
Cancer Medicine|August 10, 2021
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancerIgor Tsaur, Isabel Heidegger, Jasmin Bektic, et al.
European Urology Oncology|August 21, 2023
Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational StudyMona Kafka, Andreas Horninger, Gianpaolo di Santo, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2012
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer riskFrancesca Demichelis, Sunita R Setlur, Samprit Banerjee, et al.
Clinical Genitourinary Cancer|January 24, 2024
Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter StudyMona Kafka, Giulia Giannini, Nastasiia Artamonova, et al.
Pageof 8